{
  "Cluster": "2",
  "CandidateSubtype": "mixed",
  "TopGenes": [
    "MYH7B",
    "PDXK",
    "SLC1A5",
    "LIX1",
    "APCDD1",
    "GRM3",
    "CHST11",
    "HOMER2",
    "FBXO32",
    "IGF2R",
    "LEF1",
    "MATN3",
    "LEPR",
    "TMX4",
    "TBX3",
    "SCRN1",
    "SERPINI1",
    "NKD1",
    "ERMP1",
    "RUNX2"
  ],
  "ProliferationScore": "0.014 (low)",
  "StemnessScore": "0.461 (intermediate)",
  "ImmuneScore": "0.049 (low)",
  "PrognosticScore": "0.000 (low)",
  "SupportingEvidence": [
    "RUNX2, MATN3, CHST11 upregulation indicates chondro-osseous/mesenchymal differentiation",
    "LEF1, NKD1, APCDD1, TBX3 suggest active Wnt/\u03b2-catenin signaling common in HB and mixed tumors",
    "Coexistence of mesenchymal markers with epithelial/tumor metabolism genes (SLC1A5, IGF2R) favors an epithelial\u2013mesenchymal mixed identity",
    "Absence of strong hepatocyte differentiation markers (e.g., ALB, TTR, GLUL) argues against pure fetal subtype"
  ],
  "SuggestedExperiments": [
    "IHC/IF: \u03b2-catenin (nuclear), LEF1, TBX3; mesenchymal markers RUNX2, SOX9, COL2A1, MATN3; epithelial markers HepPar-1, AFP",
    "Spatial transcriptomics or RNA-ISH for RUNX2/MATN3 and EPCAM/ALB to demonstrate mixed epithelial\u2013mesenchymal regions",
    "Genetics: CTNNB1 mutation testing; copy-number inference from scRNA-seq",
    "Lineage analysis: trajectory/RNA velocity to assess epithelial\u2013mesenchymal transitions",
    "Functional: Wnt pathway reporter or TCF/LEF target expression; glutamine dependence assays for SLC1A5"
  ]
}